Updated
Updated · Bloomberg · Jun 11Kardigan Seeks $373.3 Million US IPO to Fund 3 Late-Stage Heart Drugs
1 articles · Updated · Bloomberg · Jun 11Summary
- Kardigan plans to sell 23.3 million shares at $14 to $16 each, targeting up to $373.3 million in a US initial public offering.
- The Princeton, New Jersey-based biotech said the proceeds will help fund three late-stage drugs aimed at cardiovascular diseases.
- At the top of the indicated range, Kardigan would be valued at about $1.4 billion based on the outstanding shares listed in its SEC filing.
Insights
Can a star team justify a $1.4B valuation when a key drug has already missed its primary goal? With the SEC proposing easier rules, is this IPO a glimpse into a riskier future for public biotech investors? Is Kardigan's AI platform a medical breakthrough or a clever strategy to attract its $373M IPO funding?